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ABSTRACT 
Purpose: Endometrial adenocarcinoma (EC) is the most common gynaecologic cancer. Up to 
90% of EC patients are obese which poses a health threat to patients post-treatment. Standard 
treatment for EC includes hysterectomy, although this has significant side effects for obese 
women at high risk of surgical complications and for women of childbearing age. This trial 
investigates the effectiveness of non-surgical or conservative treatment options for obese 
women with early stage EC. The primary aim is to determine the efficacy of: levonorgestrel 
intrauterine device (LNG-IUD); with or without metformin (an antidiabetic drug); and with 
or without a weight loss intervention to achieve a pathological complete response (pCR) in 
EC at six months from study treatment initiation. The secondary aim is to enhance 
understanding of the molecular processes and to predict a treatment response by investigating 
EC biomarkers. 
Methods: An open label, three-armed, randomised, phase-II, multi-centre trial of LNG-IUD ± 
metformin ± weight loss intervention. 165 participants from 28 centres are randomly assigned 
in a 3:3:5 ratio to the treatment arms. Clinical, quality of life and health behavioural data will 
be collected at baseline, six weeks, three and six months. EC biomarkers will be assessed at 
baseline, three and six months. 
Conclusions: There is limited prospective evidence for conservative treatment for EC. Trial 
results could benefit patients and reduce health system costs through a reduction in 
hospitalisations and through lower incidence of adverse events currently observed with 
standard treatment.  
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INTRODUCTION 
 
Endometrial adenocarcinoma (EC) is the most common gynaecologic malignancy in the 
developed world [1]. Type 1 EC is often associated with well-differentiated tumours with no 
or minimal invasion into the surrounding myometrium and carries a good prognosis [2]. 
Endometrial Hyperplasia with Atypia (EHA) is precancerous and refers to the excessive 
proliferation of endometrial glands that show cytological atypia [3, 4]. Trimble et al. reported 
a 43% incidence of EC in patients with a preoperative diagnosis of EHA [5]. Obesity is the 
main risk factor for EC with more than 60% of patients reported as obese [2, 6, 7]. Obesity is 
associated with more detailed preoperative assessments and intensive postoperative care, and 
obese patients have an increased risk of premature death due to associated comorbidities [8, 
9].  
 
Current standard treatment for EC and EHA is total hysterectomy and bilateral salpingo-
oophorectomy with or without surgical staging. Five year disease-free survival ranges from 
95-80% in stage 1 EC [10]. However, while the relative innocuousness of the tumour and 
radical surgery offer excellent survival prospects, drivers for change include poor surgical 
recovery [11], surgical adverse events [12, 13], and greater treatment costs [11, 14]. Also, 
surgical treatment of women of childbearing age results in irrevocable infertility [15-18]. As 
such, conservative treatment is a meaningful quality of life goal for selected cases [5]. The 
femme trial will investigate the effectiveness of a levonorgestrel intrauterine device (LNG-
IUD; Mirena®), metformin and weight loss intervention. 
 
Metformin (dimethylbiguanide) is widely used to treat Type 2 Diabetes Mellitus. There is an 
association between diabetes and cancer [19, 20] and clinical observations have highlighted 
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metformin as a potential anti-cancer therapy [21]. Schuler et al. (2013) conducted a window 
of opportunity study where 20 women with EC were treated with 850mg metformin once 
daily for 1-4 weeks before hysterectomy. The study observed a significantly reduced mean 
Ki-67 index (p<0.008) from pre- to post-treatment [22]. Soliman and colleagues reported the 
first window of opportunity study of metformin and found a decrease in post-treatment AKT 
and s6 expression after metformin treatment.  However, in contrast to Schuler et al. they 
found no significant difference in ki67 and caspase 3 expression between pre- and post-
treatment samples [23].   
 
Weight loss interventions are feasible and safe [24], and already in use by gynaecological 
oncologists to make women eligible for surgery. Weight loss of 7% body weight induces a 
large biological effect (e.g. reduces incidence of diabetes by 58% [25], and hypertension by 
26% [26]). A 6-month weight loss and physical activity intervention trial for 
overweight/obese EC survivors (n=75) found that 26% of intervention participants lost ≥ 5% 
of their weight compared with 9% of usual care participants. However, the study was limited 
by small sample size, biomarkers or tumour responses were not studied, and although 
promising, the clinical implications are unclear as <7% weight loss was achieved [27]. 
 
The primary aim of this phase II, three-arm randomised trial is to determine the efficacy of 
LNG-IUD ± metformin ± weight loss intervention to achieve a pathological complete 
response (pCR) at 6 months. Secondary aims are to predict the response to LNG-IUD ± 
metformin through clinical (body size), blood and tissue predictive biomarkers and to 
increase our molecular understanding of the biological pathways of “early” EC.  
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METHODS 
 
Design: This trial has been designed as an open label, randomized phase II trial (Figure 1). 
The study protocol was approved by the Human Research Ethics Committees of all 
institutions that enrol patients. Randomisation aims to eliminate selection bias rather than 
formal comparison of groups. Eligibility and exclusion criteria are detailed in Table 1. To 
minimise the risk of enrolling patients with aggressive EC, patients are only eligible for 
enrolment if they have apparent stage 1 disease (absence of lymphadenopathy or pelvic 
masses), endometrioid cell type and FIGO grade 1 EC and no lymph vascular space invasion 
on curettings, no or only minimal myometrial invasion on MRI (to exclude deeply invasive 
cancers), and a serum CA125 of 30 U/ml or less[28].  
 
In addition to the established criteria for low-risk disease (CT and MRI scan, FIGO grade) we 
will also only offer patients with negative serum CA125 participation in the trial. We 
previously found that baseline CA125 was the most accurate predictor of extrauterine 
disease, even outperforming FIGO grade [29]. Considering the strict criteria above, we can 
expect that we will find advanced or aggressive disease in less than 3% of patients. In 
addition, all patients will undergo a safety check at 3 months from baseline. 
 
We plan to record medical co-morbidities and use the Charlson index score [30] to document 
them in a standardised way for comparison purposes. 
 
Randomisation has been programmed via an interactive Voice Response System. 
Participants will be randomly allocated to LNG-IUD: LNG-IUD + weight loss intervention: 
LNG-IUD + metformin in a 3:3:5 ratio. Participants will be stratified by body mass index 
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(BMI) categories 30 kg/m2 - 40 kg/m2 and ≥40 kg/m2, menopausal status, treatment centre 
and diagnosis (EHA versus EC). Patients not eligible for Metformin are still eligible to be 
randomised to either LNG-IUD or LNG-IUD plus weight loss and patients not eligible for 
weight loss are still eligible to be randomised to LNG-IUD or LNG-IUD plus metformin. 
 
Interventions: LNG-IUD is currently approved by the Australian Therapeutic Goods 
Administration (TGA) for contraception, treatment of idiopathic menorrhagia and prevention 
of endometrial hyperplasia during oestrogen replacement therapy and will be placed into the 
uterine cavity releasing 52 mg levonorgestrel at a rate of 20 microgram/24 hours. In addition 
to LNG-IUD, 75 patients will receive metformin with meals, 1000mg daily. This dose is 
similar to clinical trials in the breast cancer adjuvant setting (NCT00909506 and 
NCT01302002) where doses between 500 mg and 1000 mg daily are given.  Metformin is 
well tolerated by the vast majority of patients without side effects. Its most common adverse 
effects [31] are gastrointestinal (diarrhoea, cramps, nausea, vomiting, increased flatulence); 
side effects are dose-dependent. The dose of 1000 mg daily can be reduced to 500 mg daily if 
required. The investigational products (LNG-IUD and metformin) have been described in 
Table 2. In addition to LNG-IUD, 45 patients will be assigned to weight loss intervention. 
They will be provided with a voucher for a comprehensive subscription to a standard weight 
loss program (Weight Watchers®). The weight loss program is an evidence-based and tested 
program of dietary intervention, which has produced consistent weight loss success for 
overweight or obese people [32]. Group meetings are held in locations throughout Australia, 
and promote a hypo-energetic diet, physical activity, social networking and support. Online 
tools feature self-audit and management resources, healthy recipes, and online social 
networking opportunities. Participants are encouraged to use the face-to-face and online 
tools, and are called every calendar month (± 3 days) by the study manager or coordinator to 
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assess their use of the program and progress with weight loss (the target is 7% weight loss). 
 
We will only provide standardised study information to all patients, but will not specifically 
inform patients not assigned to the weight loss group about weight loss. Patients my seek 
support for weight loss on their own terms, and we will monitor how many patients may 
enrol in weight loss programs in each group. The  LNG-IUD group will allow us to assess the 
effect of hormone treatment without confounding by weight loss. 
 
Treatment Adverse events will be managed by local investigators and documented 
according to current good clinical practice guidelines [33] (Common Toxicity Criteria V4 
[34]).  
 
Study Assessments and Procedures 
A summary of study assessments and procedures at baseline, day 1, week 1, week 6, 3 
months and 6 months has been outlined in Table 3. 
 
Baseline assessments 
Baseline assessments will be performed according to the trial standard operating procedures 
(SOPs), including CT and MRI scans, medical history, concomitant medical co-morbidities 
documented and scored according to Charlson [30], fasting blood sample, as well as weight, 
height, waist/hip circumference. According to standard referral pathways, endometrial tissue 
will be obtained by a hysteroscopy, dilatation and curette (D&C) by the treating 
gynaecological oncologist. Histopathological tumour board review will confirm cell type and 
grade of differentiation. Central histopathology review will be facilitated at the end of the 
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trial. Blood samples will be processed for shipping and formalin-fixed D&C blocks will be 
obtained for molecular biomarker analysis.  
 
We will use the same self-administered questionnaires as in our previous randomised trial 
with endometrial cancer patients to allow comparison across studies: Functional Assessment 
of Cancer Therapy Questionnaire, plus endometrial cancer module[35] [36]; Hospital 
Anxiety and Depression Scale[37]; Health Services use questionnaire [38];  Pelvic Floor 
Distress Inventory[39]; Victorian Cancer Council Food Frequency Questionnaire. 
 
Formalin-fixed samples (FFPE) and serum biomarkers will be assessed at baseline, 3 and 6 
months. An initial immunohistochemistry (IHC) study of biomarkers will be performed using 
markers aimed to develop an IHC- based predictive assay for LNG-IUD and/or metformin. 
To allow for quantitative determination of protein expression at different time points 
automated algorithms will be used. Molecular biomarker testing on tumour tissue will be 
followed by genetic testing for germline mutations to determine the origin of mutation. We 
will measure levels of IGF1, IGFBP-1 and 3, sex-hormone binding globulin, total and free 
oestradiol, progesterone, leptin, prolactin, active and total ghrelin, and adiponectin using 
commercial ELISA kits. Blood samples for germline DNA will be taken to assist future 
studies. Serum will also be used to investigate the metabolic balances and EC-related 
endocrine profiles.  
 
Biomarkers will include PTEN and p-S6K as surrogate markers of PI3K-AKT-mTOR 
activity and LKB1, which will be expected to increase after metformin treatment. ERα, PRα 
and PRβ will also be assessed with special emphasis placed on individual quantification of 
stromal and epithelial components as more evidence accrues that stromal HR expression may 
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play an important role in EAC. Finally a number of ER and PR response genes will be 
assessed to confirm progesterone action as well as the proliferative marker Ki-67. Our 
hypothesis is that metformin treatment will lead to a prolonged increase in PR even in the 
presence of progesterone, which will lead to a more durable response to progesterone. DNA 
will also be extracted from FFPE sections and common somatic mutations in PR, P53, PTEN, 
PI3KCA, ARID1A, KRAS, CTNNB1 will be assessed using iPLEX technology on a 
MassARRAY Compact Analyser (Sequenom Inc., San Diego, USA). 
 
Efficacy assessments 
At 3 months endometrial tissue will be obtained (safety check) to exclude progression of 
EHA or EC. At this point in time we will not attempt to ascertain a pathological complete 
response (pCR). If a patient progresses (i.e., patients with EHA progress to Grade 1 EC), 
develop grade 2 or 3 cancer or develop other histological cell types than endometrial) at 3 
months, the patient will be returned to routine clinical care; surgical treatment (including a 
hysterectomy if appropriate) will be offered.  
 
At 6 months endometrial tissue will be obtained and pCR will be assessed (primary study 
endpoint). After 6 months, women will be returned into the care of their usual clinician and 
will make a decision about the most appropriate treatment with their clinician on an 
individual basis.   
 
The primary aim of this trial is to determine the efficacy of LNG-IUD ± metformin ± weight 
loss to achieve a pCR at 6 months from randomization, defined as absence of invasive EC or 
EHA at 6-month [dilation and curette (D&C)]. Secondary aims include to predict the 
response to LNG-IUD ± metformin through clinical (body size), blood and tissue predictive 
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biomarkers and to increase our molecular understanding of the biological pathways of “early” 
EC.  
 
Physical activity: Exercise level (sedentary, moderately active, and sufficiently active) will 
be measured using the Active Australia Survey[40], while the Hospital Anxiety and 
Depression Scale (HADS)[37] will briefly measure current anxiety and depressive 
symptomatology. [41].  
 
Quality of life: The FACIT (Functional Assessment of Chronic Illness Therapy) 
Measurement System is a 43-item questionnaire with 5 domain-specific subscales: physical 
well-being; social/family wellbeing; emotional well-being, functional well-being and EC 
specific additional concerns[42].  
 
Health services use: Seven items assessing health care utilization during the past 6 months 
were adapted from Health Care Utilization items developed by the Stanford Patient Education 
Research Centre[43], which have excellent test-retest reliability ranging from 0.76 - 0.97 and 
validly assess use of such services[43].  
 
Pelvic floor distress: the Pelvic Floor Distress Inventory (PFDI) provides a standardized, 
reproducible assessment of the patient’s symptoms and their effect on daily life [44].  
 
Diet: The Cancer Council Victoria Food Frequency Questionnaire will be used to assess diet 
as it has acceptable levels of reliability and validity when compared with seven-day weighted 
food records, and has been successfully used over the telephone with cancer survivors[45]. 
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Further questionnaires will measure self-efficacy[46] and social support[47] .  
 
Sample Size 
Our published meta-analysis[48] suggests that the average pCR rate, based on 12 studies, was 
68% (95% CI: 45%-86%). We anticipate that the true pCR rate will be closer to the lower 
confidence limit of 45%. Using this as the basis and a 3 (LNG-IUD): 3 (LNG-IUD + 
metformin): 5 (LNG-IUD + weight loss intervention) randomisation (to minimise selection 
bias), a 60% or higher pCR rate with any combination treatment would provide strong 
evidence for informing a subsequent phase III trial. Additionally, in the event that the pCR 
within the LNG-IUD only group is better than 45%, the study would also have more than 
80% power with 95% confidence to rule out a 60% LNG-IUD only pCR in favour of a 75% 
in the LNG-IUD plus metformin or LNG-IUD plus weight loss groups; or alternatively also 
>80% power to rule out a 65% pCR in favour of 80% pCR rate. 
 
Statistical Analyses 
We will calculate the proportion (+95% confidence intervals (CI)) of patients with pCR of the 
EHA or EC at 6 months within the LNG-IUD ± metformin ± weight loss groups. We will 
measure quality of life at baseline week 1, week 6, month 3 and at 6 months for explorative 
purposes. Descriptive analysis will calculate the mean or median change in molecular 
markers in each group. In particular, this study will investigate changes in molecular 
biomarker expression to increase our understanding of molecular mechanisms leading to 
pCR, persistence or progression. Additionally, appropriate regression methods will be used to 
explore for potential predictors of pCR at 6 months. Estimations from this trial will form the 
basis of designing subsequent phase III trials based on level of activity observed. 
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DISCUSSION 
Our feMMe trial (NCT01686126) is innovative as it will test the efficacy of three 
interventions (LNG-IUD, LNG-IUD + metformin, LNG-IUD + weight loss intervention) in 
the setting of a phase II randomised design. We will enrol obese patients with low-grade and 
“early” EC or EHA because the prognosis of these patients is excellent and even non-
responders will likely not be harmed by having been withheld treatment for 6 months.  
 
We have chosen LNG-IUD as the standard treatment arm, being well aware that the evidence 
for LNG-IUD to treat EC and EHA is based on case series and a meta-analysis including a 
total of 20 patients. However, while the efficacy of LNG-IUD is poorly documented, it is 
currently offered to many young women with early EC or EHA who wish to retain fertility or 
to women in poor general health who are at high risk of developing surgical complications by 
undergoing a hysterectomy.  
 
A meta-analysis of outcomes after progestin treatments found oral and intrauterine treatments 
were similarly effective, although there are only 12 high quality studies in total that included 
at least 10+ eligible patients with EHA or endometrioid adenocarcinoma (EC) in either the 
oral or intrauterine treatment arm; patients 6+ months of treatment; not receiving other 
treatments,  were available [48]. In patients with stage 1 EC treated with intrauterine 
progestins, the weighted mean pCR rate was 68% (95% CI 45-86%), but was only based on 
one published and one unpublished series [48]. The use of oral progestins for EC is 
problematic, as side effects include thrombo-embolic complications (DVT, PE, stroke), 
weight gain, and the onset or worsening of Type 2 diabetes mellitus [48]. Currently, oral 
progestins are mainly used to treat EC recurrence. In contrast, LNG-IUD is not known to 
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cause systemic side effects. However, recurrences are common after removal of LNG-IUD 
[49, 50]. 
 
The current study is innovative as it will test combinations of pharmaceutical and behavioural 
interventions with the hope to reverse the hormonal and metabolic imbalances associated 
with obesity and insulin resistance leading to EC [51]. Metformin, an oral anti-diabetic, was 
chosen as evidence is accumulating for its potential as an anti-cancer drug and 
epidemiological studies suggest that metformin use is associated with improved prognosis in 
patients with various types of cancers [21].  Several reports have established a direct action of 
metformin on cancer cells [19]. Metformin activates adenosine monophosphate (AMP)-
activated protein kinase (AMPK) via its upstream kinase LKB1. Activation of AMPK effects 
cellular metabolism and intracellular signalling. The overall effects of AMPK activation on 
mammalian metabolism are compatible with the hypothesis that it is a tumour suppressor that 
promotes the oxidative metabolism that is typical of quiescent cells, rather than the glycolytic 
metabolism typical of tumour cells. AMPK activation also causes inhibition of mTOR, [52, 
53]. mTOR is frequently activated in EC cells [54] and  associated with resistance to 
progestins [55, 56]. Metformin has been shown to induce cell cycle arrest and apoptosis and 
causes up-regulation of PR and reverses resistance to progesterone in vitro in an mTOR 
dependent manner[52, 53, 57].  
 
Previous investigators recently completed a nude mouse endometrial cancer xenograft study 
in which mice were inoculated with EC cells and then treated with oral metformin. Mice 
treated with metformin were found to have significant reductions in mean tumour volume at 
necropsy compared to control treated mice. In a window of opportunity study 20 women with 
EC were treated with 850mg metformin once daily for 1-4 weeks before hysterectomy, and a 
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strong reduction in the mean Ki-67 index was observed [22].  
 
We chose a weight loss intervention because obesity is undeniably the biggest risk factor for 
the development of EC. Recurrences after conservative treatment for EC are common and 
reversal of the main risk factor seems a plausible necessity to maintain a response to LNG-
IUD. Weight loss interventions are feasible and safe, and already being implemented by 
gynaecologic oncologists to make women eligible for surgery, as well, as in the post-
treatment setting [25, 26, 58] [27]. The standard weight loss program used in this study is 
widely available and effective [32]. 
 
Retrospective case series and meta-analyses are available on the use of LNG-IUD for the 
reversal of EHA and EC. In addition, several prospective, randomised and non-randomised 
clinical trials of LNG-IUD are underway. Trial NCT01594879 is registered on clinical 
trial.gov as is a single-arm, non-randomised clinical trial examining the efficacy of LNG-IUD 
and Medroxyprogesterone acetate (MPA) to treat patients with endometrial hyperplasia with 
atypia and endometrial adenocarcinoma. The study outcome is pathological response at 24 
months and a total of 39 patients are planned to be enrolled. In 2008 the MD Anderson 
Cancer Center commenced enrolment into a non-randomised phase 2 clinical trial on LNG-
IUD in patients with EHA and EC. The main study endpoint pCR will be assessed in 50 
patients enrolled by 2015 (clinicaltrial.gov NCT00788671). The USC/Norris Comprehensive 
Cancer Center will commence enrolment of a phase 2 RCT enrolling 130 patients to receive 
either megestrol acetate or LNG-IUD for 18 months (NCT01943058).  
 
There are also a number of trials of metformin in women with EC that are currently underway 
or in the planning phase. For example, the Gynaecologic Oncology Group (GOG) is testing 
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paclitaxel, carboplatin, and metformin hydrochloride and comparing it to paclitaxel, 
carboplatin, and placebo in stage 3 or 4 or recurrent EC (NCT02065687). Whilst 
investigators from the MD Anderson Cancer Center are conducting an efficacy trial of the 
molecular effects of metformin, including physiologic changes in insulin/glucose metabolism 
and the mTOR pathway (NCT01205672), and they are investigating whether metformin 
and/or a lifestyle intervention can prevent EC in obese post-menopausal women 
(NCT01697566). 
 
We hope that the current study will extend the low-level evidence for the effectiveness of 
LNG-IUD in the treatment of low-grade, “early” EC and EHA. The feMMe trial will confirm 
or readjust pCR rates following treatment with LNG-IUD with or without metformin and a 
weight loss intervention. We hope that LNG-IUD can be confirmed as an alternative 
treatment of EC and EHA in obese women with multiple medical comorbidities and in young 
women who would lose fertility irrevocably through surgery. In Australia, treatment is 
streamlined with almost all EC cases and an increasing number of women with EHA 
routinely referred to gynaecological oncologists. Compared to the United States and Europe, 
Australia has a competitive advantage to contribute to the knowledge about this growing 
health issue. 
 
CONCLUSION 
If successful, the results of this trial could significantly reduce the adverse event rate 
currently observed when women receive standard surgical care and thus greatly benefit 
patients and reduce costs for the health care system.  
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